Current label evidence
Wegovy and Zepbound include itching inside grouped reaction categories
The June 2026 Wegovy label reports injection-site reactions in 1.4% of treated adults and 1% of placebo-treated adults in weight-reduction trials. That category includes injection-site itching, redness, inflammation, firmness, and irritation. The April 2026 Zepbound label reports injection-site reactions in 6%, 8%, and 8% of patients receiving 5 mg, 10 mg, and 15 mg versus 2% receiving placebo; its category includes bruising, redness, itching, pain, rash, and unspecified reaction. Neither label provides an itch-only incidence, expected size, onset, or duration.
- Do not say that 1.4% of Wegovy patients or 6% to 8% of Zepbound patients developed itching; those are grouped-reaction rates.
- Trial rates describe specific products, populations, doses, and study methods and cannot diagnose one person’s symptom.
- Do not compare grouped percentages across products as proof that one medicine is less likely to itch because definitions and trial settings differ.
Product and route identity
Match the symptom to the exact injection—not the GLP-1 class name alone
Current Mounjaro adult placebo-controlled trials report injection-site reactions in 3.2% of treated patients versus 0.4% with placebo, without publishing an itch-only rate. Current Ozempic trials report local discomfort or redness in 0.2% of treated patients and do not provide an itching rate. Wegovy now includes both subcutaneous injection and once-daily oral tablets; only the injection presentation has an injection site. Brand, active ingredient, route, device or vial, inactive ingredients, and pharmacy label therefore matter before interpreting a local symptom.
- Confirm whether the exposure was semaglutide or tirzepatide and whether it was an FDA-approved branded product or a patient-specific compounded preparation.
- Do not transfer an injection-site percentage to oral Wegovy tablets, another brand, a compounded vial, an unlabeled product, or a research-use material.
- Do not skip, repeat, increase, split, retime, or switch a dose or product from an online symptom chart.
Local versus systemic symptoms
An itchy spot, spreading hives, infection signs, and serious allergy are different questions
A small itchy area near an injection and widespread hives or swelling should not be treated as the same pattern. Current semaglutide and tirzepatide labels warn about serious hypersensitivity reactions, including anaphylaxis and angioedema. Increasing warmth, pain, swelling, spreading redness, pus, drainage, red streaks, fever, or feeling acutely unwell can also require in-person assessment for infection or another local complication. An online photo cannot determine whether itching reflects ordinary irritation, allergy, infection, an inactive ingredient, antiseptic or adhesive exposure, a skin condition, or another cause.
- Call emergency services for trouble breathing, throat tightness, facial or tongue swelling, fainting, severe confusion, or rapidly developing widespread hives or swelling.
- Seek prompt local assessment for rapidly spreading redness, severe or escalating pain or swelling, fever or chills, pus, red streaks, blistering, darkening, or skin breakdown.
- Contact the prescriber for persistent, recurrent, spreading, sleep-disrupting, or treatment-limiting itching even when emergency features are absent.
Site and exposure review
Record what touched the skin and what changed before blaming the medicine
Useful details include the time from administration to itching, exact location, border and size trend, rash or hives, warmth, tenderness, swelling, firmness, drainage, fever, and symptoms away from the site. Also report whether the site was already irritated and whether there was a new alcohol prep, adhesive, bandage, skin cleanser, lotion, device, needle, supply kit, refill, formulation, concentration, shipment, or storage concern. These clues help a clinician assess possibilities but do not prove contact dermatitis, medication allergy, contamination, or technique error.
- Use the site-selection and rotation instructions supplied with the exact product and avoid skin that is red, swollen, bruised, scarred, hardened, or otherwise damaged.
- Preserve the patient label, pharmacy and lot or prescription details, packaging, storage history, supply information, and dated photos when the care team requests them.
- Do not scratch open the skin, squeeze a lump, apply leftover prescription creams, start an antihistamine plan, or use another injection as a test without clinician guidance.
Compounded-product boundary
A compounded vial does not inherit a branded pen’s reaction rate
Wegovy, Ozempic, Zepbound, and Mounjaro are FDA-approved finished drug products with product-specific labels. A patient-specific compounded semaglutide or tirzepatide prescription is not an FDA-approved finished drug product and can differ in presentation, concentration, inactive ingredients, container, supplies, storage directions, and beyond-use date. A branded label can provide context, but it cannot validate a compounded product or establish why one site itches.
- Confirm the prescriber, dispensing pharmacy, active ingredient, route, concentration, label, supplies, inactive ingredients when available, storage history, and adverse-event contact.
- Ask the dispensing pharmacy about a changed label or concentration, delayed or warm shipment, damaged package, cloudy or discolored solution, particles, or uncertain storage before use.
- Avoid research-only vials, counterfeit pens, unlabeled blends, copied injection maps, reconstitution recipes, and sellers that skip prescription-first clinician review.